{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:54:48Z","timestamp":1771977288859,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007514","name":"University of Pisa","doi-asserted-by":"publisher","award":["PRA_2020_57"],"award-info":[{"award-number":["PRA_2020_57"]}],"id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Our study aims at providing evidence on patterns of use of biologic drugs for psoriasis in Tuscany, Italy. We conducted a drug-utilization study based on administrative databanks of Tuscany (EUPAS45365) from 2011 to 2019. We selected new users of etanercept, infliximab, adalimumab, ustekinumab, or secukinumab between 1 January 2011 and 31 December 2016. We considered subjects with psoriasis and followed subjects until the end of the study period (three years after the first dispensation of biologic drug for psoriasis) or the patient\u2019s death, whichever came first. We censored subjects for pregnancy or neoplasia. For each subject, we defined the state as the weekly coverage of one of the biologic drugs of interest. We then defined the switch as the change from a state to another one. A total of 7062 subjects with a first dispensation of a PSObio drug in the inclusion period was identified, and 1839 (52.9% female, 51.6 mean age) patients were included in the analysis. Among new users of adalimumab (N = 770, 41.9%), one third showed a continuous behaviour whereas the others moved to etanercept and ustekinumab. New users of etanercept (N = 758, 41.2%), had the highest proportion of switchers, with adalimumab most often being the second choice. New users of infliximab (N = 159, 8.6%) experienced the highest proportion of treatment discontinuation. The present study suggests that the majority of patients treated with PSObio drugs do not switch from one active ingredient to another. However, patients who started biological therapy with etanercept had the highest frequency of switching to other PSObio drugs, whereas those who started with secukinumab or ustekinumab had the lowest.<\/jats:p>","DOI":"10.3390\/ijerph19116799","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T04:46:23Z","timestamp":1654145183000},"page":"6799","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1778","authenticated-orcid":false,"given":"Sabrina","family":"Giometto","sequence":"first","affiliation":[{"name":"Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Tillati","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Baglietto","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-1060","authenticated-orcid":false,"given":"Nicola","family":"De Bortoli","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-2357","authenticated-orcid":false,"given":"Marco","family":"Conte","sequence":"additional","affiliation":[{"name":"CESP, U1018 INSERM, Universit\u00e9 Paris-Saclay, UVSQ, H\u00f4pital Paul Brousse B\u00e2timent 15\/16, CEDEX, 94807 Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8486","authenticated-orcid":false,"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"},{"name":"Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-877X","authenticated-orcid":false,"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[{"name":"Tuscan Regional Healthcare Agency, 50141 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5902","authenticated-orcid":false,"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris-Part 1: Treatment and Monitoring Recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0190-9622(99)70008-3","article-title":"A Randomized Comparison of Narrow-Band TL-01 Phototherapy and PUVA Photochemotherapy for Psoriasis","volume":"41","author":"Gordon","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archderm.1984.01650450051017","article-title":"Psoralens and UV-A and UV-B Twice Weekly for the Treatment of Psoriasis","volume":"120","author":"Diette","year":"1984","journal-title":"Arch. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0625.1992.tb00071.x","article-title":"A Reappraisal of the Use of 5-methoxypsoralen in the Therapy of Psoriasis","volume":"1","author":"Ortel","year":"1992","journal-title":"Exp. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0140-6736(81)92137-1","article-title":"ORAL 8-METHOXYPSORALEN PHOTOCHEMOTHERAPY OF PSORIASIS. The European PUVA Study: A Cooperative Study among 18 European Centres","volume":"317","author":"Henseler","year":"1981","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Amoruso, G.F., Nistic\u00f2, S.P., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab May Improve Renal Function in Psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dastoli, S., Nistic\u00f2, S.P., Morrone, P., Patruno, C., Leo, A., Citraro, R., Gallelli, L., Russo, E., de Sarro, G., and Bennardo, L. (2022). Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020294"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Woo, Y.R., Cho, D.H., and Park, H.J. (2017). Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122684"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"del Duca, E., Morelli, P., Bennardo, L., di Raimondo, C., and Nistic\u00f2, S.P. (2020). Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228436"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v040.i04","article-title":"Analyzing and Visualizing State Sequences in R with TraMineR","volume":"40","author":"Gabadinho","year":"2011","journal-title":"J. Stat. Softw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic Therapy Adherence, Discontinuation, Switching, and Restarting among Patients with Psoriasis in the US Medicare Population","volume":"74","author":"Doshi","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000444581","article-title":"Patient Adherence to Biologic Agents in Psoriasis","volume":"232","author":"Hsu","year":"2016","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09546634.2019.1687828","article-title":"Treatment Adherence and Persistence of Five Commonly Prescribed Medications for Moderate to Severe Psoriasis in a U.S. Commercially Insured Population","volume":"32","author":"Wu","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Piragine, E., Petri, D., Martelli, A., Janowska, A., Dini, V., Romanelli, M., Calderone, V., and Lucenteforte, E. (2022). Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061506"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2013.10.019","article-title":"Efficacy of Switching between Tumor Necrosis Factor-Alfa Inhibitors in Psoriasis: Results from the Italian Psocare Registry","volume":"70","author":"Piaserico","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","article-title":"Efficacy and Safety of Adalimumab in Patients with Psoriasis Previously Treated with Anti-Tumour Necrosis Factor Agents: Subanalysis of BELIEVE","volume":"25","author":"Ortonne","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2006.12.003","article-title":"Adalimumab for Severe Psoriasis and Psoriatic Arthritis: An Open-Label Study in 30 Patients Previously Treated with Other Biologics","volume":"57","author":"Papoutsaki","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jdv.15077","article-title":"Psoriasis Area and Severity Index Response in Moderate-Severe Psoriatic Patients Switched to Adalimumab: Results from the OPPSA Study","volume":"32","author":"Talamonti","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2009.08.040","article-title":"Efficacy and Safety of Adalimumab in Patients with Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Etanercept","volume":"63","author":"Bissonnette","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2133.2010.09950.x","article-title":"Switching from Etanercept to Adalimumab Is Effective and Safe: Results in 30 Patients with Psoriasis with Primary Failure, Secondary Failure or Intolerance to Etanercept","volume":"163","author":"Lecluse","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/09546634.2014.952611","article-title":"Efficacy, Tolerability and Safety of Switching from Etanercept to Infliximab for the Treatment of Moderate-to-Severe Psoriasis: A Multicenter, Open-Label Trial (TANGO)","volume":"26","author":"Ayala","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000497274","article-title":"Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience","volume":"235","author":"Chiricozzi","year":"2019","journal-title":"Dermatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12793","DOI":"10.1111\/dth.12793","article-title":"When IL-17 Inhibitors Fail: Real-Life Evidence to Switch from Secukinumab to Adalimumab or Ustekinumab","volume":"32","author":"Damiani","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaad.2007.03.035","article-title":"Infliximab in the Treatment of Psoriasis in Patients Previously Treated with Etanercept","volume":"57","author":"Haitz","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaad.2011.10.020","article-title":"The Efficacy and Safety of Infliximab in Patients with Plaque Psoriasis Who Had an Inadequate Response to Etanercept: Results of a Prospective, Multicenter, Open-Label Study","volume":"67","author":"Gottlieb","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2133.2010.09893.x","article-title":"Switching to Adalimumab in Patients with Moderate to Severe Psoriasis Who Have Failed on Etanercept: A Retrospective Case Cohort Study","volume":"163","author":"Woolf","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/09546634.2014.933166","article-title":"Efficacy and Safety of Adalimumab in Psoriatic Patients Previously Treated with Etanercept in a Real-World Setting","volume":"26","author":"Fonseca","year":"2014","journal-title":"J. Dermatol. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1346-8138.13860","article-title":"Switching of Biologics in Psoriasis: Reasons and Results","volume":"44","author":"Honda","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1346-8138.14834","article-title":"Sustainability and Switching of Biologics for Psoriasis and Psoriatic Arthritis at Fukuoka University Psoriasis Registry","volume":"46","author":"Bayaraa","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug Survival of Biologic Therapy in a Large, Disease-based Registry of Patients with Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.16214","article-title":"Real-World, Long-Term Treatment Patterns of Commonly Used Biologics in Canadian Patients with Moderate-to-Severe Chronic Plaque Psoriasis","volume":"49","author":"Gooderham","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_35","first-page":"230","article-title":"Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics","volume":"45","author":"Tokuyama","year":"2020","journal-title":"Tokai J. Exp. Clin. Med."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/11\/6799\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:23:39Z","timestamp":1760138619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/11\/6799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijerph19116799"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19116799","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}